SEC Form 4 · accession 0001140361-17-040667
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristina Burow
Director
Period of report
Nov 1, 2017
Accepted (ET)
Nov 2, 2017 · 11:50 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.91 | Nov 1, 2017 | A | 5,315 | A | — | Nov 1, 2027 | Common Stock | 5,315 | 5,315 | D |
Explanation of responses
- F1The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.